Polyethylene glycol 3350 in occasional constipation: A one-week, randomized, placebo-controlled, double-blind trial

Table 1 Patient demographics and baseline characteristics n (%)

Summary	Treatment group		All subjects	P value1
	PEG 3350	Placebo
ITT subjects	102	101	203
Gender				0.2165
Male	25 (24.5)	33 (32.7)	58 (28.6)
Female	77 (75.5)	68 (67.3)	145 (71.4)
Age (yr)				0.7361
n	102	101	203
Mean ± SD	45.8 ± 12.52	45 ± 14.15	45.4 ± 13.33
Race				0.3340
American Indian	0	2 (2.0)	2 (1.0)
Alaskan native	0	0	0
Asian	0	0	0
Black/African American	7 (6.9)	9 (8.9)	16 (7.9)
Native Hawaiian	0	0	0
White	81 (79.4)	71 (70.3)	152 (74.9)
Hispanic or Latino	14 (13.7)	19 (18.8)	33 (16.3)
Weight (kg)				0.5257
n	102	101	203
Mean ± SD	80.2 ± 19.11	79.7 ± 21.19	79.9 ± 20.12
On average, how many successful bowel movements does the subject have per week?				0.8232
0-2	36 (35.3)	35 (34.7)	71 (35.0)
3-5	44 (43.1)	40 (39.6)	84 (41.4)
6-8	22 (21.6)	25 (24.8)	47 (23.2)
> 9	0	1 (1.0)	1 (0.5)
What type of laxative is this?				0.6775
Stimulant	57 (55.9)	63 (62.4)	120 (59.1)
Bulk forming fiber	12 (11.8)	15 (14.9)	27 (13.3)
Lubricant	3 (2.9)	2 (2.0)	5 (2.5)
Osmotic	8 (7.8)	4 (4.0)	12 (5.9)
Carbon dioxide releasing	0	0	0
Stool softener	18 (17.6)	15 (14.9)	33 (16.3)
Combination	2 (2.0)	0	2 (1.0)
Other	2 (2.0)	2 (2.0)	4 (2.0)

¹Wilcoxon Rank-Sum test was used to assess homogeneity among treatment groups of baseline continuous variables, and Fisher’s exact test was used to evaluate categorical variables. ITT: Intent to treat; PEG: Polyethylene glycol.